NO329232B1 - Medikament for lokal paforing og framgangsmate for framstilling av en fibrinogenholdig losning - Google Patents
Medikament for lokal paforing og framgangsmate for framstilling av en fibrinogenholdig losning Download PDFInfo
- Publication number
- NO329232B1 NO329232B1 NO20015510A NO20015510A NO329232B1 NO 329232 B1 NO329232 B1 NO 329232B1 NO 20015510 A NO20015510 A NO 20015510A NO 20015510 A NO20015510 A NO 20015510A NO 329232 B1 NO329232 B1 NO 329232B1
- Authority
- NO
- Norway
- Prior art keywords
- allogeneic
- fibrinogen
- medicine according
- active substances
- virus
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 76
- 229940079593 drug Drugs 0.000 title claims description 73
- 108010049003 Fibrinogen Proteins 0.000 title claims description 64
- 102000008946 Fibrinogen Human genes 0.000 title claims description 64
- 229940012952 fibrinogen Drugs 0.000 title claims description 63
- 238000000034 method Methods 0.000 title claims description 48
- 230000000735 allogeneic effect Effects 0.000 claims description 68
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 51
- 108010073385 Fibrin Proteins 0.000 claims description 49
- 102000009123 Fibrin Human genes 0.000 claims description 49
- 241000700605 Viruses Species 0.000 claims description 49
- 229950003499 fibrin Drugs 0.000 claims description 48
- 206010052428 Wound Diseases 0.000 claims description 42
- 208000027418 Wounds and injury Diseases 0.000 claims description 42
- 239000013543 active substance Substances 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 40
- 230000008569 process Effects 0.000 claims description 38
- 108090000190 Thrombin Proteins 0.000 claims description 29
- 230000002779 inactivation Effects 0.000 claims description 29
- 229960004072 thrombin Drugs 0.000 claims description 29
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 28
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 28
- 210000002744 extracellular matrix Anatomy 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 20
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 20
- 108060008539 Transglutaminase Proteins 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 102000003601 transglutaminase Human genes 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 16
- 229940088598 enzyme Drugs 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 102000008847 Serpin Human genes 0.000 claims description 14
- 108050000761 Serpin Proteins 0.000 claims description 14
- 239000003001 serine protease inhibitor Substances 0.000 claims description 14
- 238000007792 addition Methods 0.000 claims description 13
- 102000010911 Enzyme Precursors Human genes 0.000 claims description 12
- 108010062466 Enzyme Precursors Proteins 0.000 claims description 12
- 230000006866 deterioration Effects 0.000 claims description 12
- 108010035532 Collagen Proteins 0.000 claims description 11
- 102000008186 Collagen Human genes 0.000 claims description 11
- 229920001436 collagen Polymers 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 230000029663 wound healing Effects 0.000 claims description 10
- 102000029816 Collagenase Human genes 0.000 claims description 9
- 108060005980 Collagenase Proteins 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 230000015271 coagulation Effects 0.000 claims description 8
- 238000005345 coagulation Methods 0.000 claims description 8
- 108010067306 Fibronectins Proteins 0.000 claims description 7
- 102000016359 Fibronectins Human genes 0.000 claims description 7
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 7
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 7
- 239000002532 enzyme inhibitor Substances 0.000 claims description 7
- 238000007711 solidification Methods 0.000 claims description 7
- 230000008023 solidification Effects 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 239000012876 carrier material Substances 0.000 claims description 5
- 230000000740 bleeding effect Effects 0.000 claims description 4
- 229960002424 collagenase Drugs 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 4
- 238000006297 dehydration reaction Methods 0.000 claims description 4
- 108010031318 Vitronectin Proteins 0.000 claims description 3
- 102100035140 Vitronectin Human genes 0.000 claims description 3
- 230000000181 anti-adherent effect Effects 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 239000003911 antiadherent Substances 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000007547 Laminin Human genes 0.000 claims description 2
- 108010085895 Laminin Proteins 0.000 claims description 2
- 102000016611 Proteoglycans Human genes 0.000 claims description 2
- 108010067787 Proteoglycans Proteins 0.000 claims description 2
- 102000007000 Tenascin Human genes 0.000 claims description 2
- 108010008125 Tenascin Proteins 0.000 claims description 2
- 108060008245 Thrombospondin Proteins 0.000 claims description 2
- 102000002938 Thrombospondin Human genes 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 238000005194 fractionation Methods 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000000021 stimulant Substances 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003399 chemotactic effect Effects 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 33
- 210000002381 plasma Anatomy 0.000 description 21
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 239000000499 gel Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 238000013461 design Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000003480 fibrinolytic effect Effects 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 239000003527 fibrinolytic agent Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 108010071289 Factor XIII Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229940012444 factor xiii Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- -1 only allogeneic Substances 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 3
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 3
- 102100035023 Carboxypeptidase B2 Human genes 0.000 description 3
- 108010035369 Cohn fraction I Proteins 0.000 description 3
- 108010088842 Fibrinolysin Proteins 0.000 description 3
- 108010001014 Plasminogen Activators Proteins 0.000 description 3
- 102000001938 Plasminogen Activators Human genes 0.000 description 3
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 3
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 229940127126 plasminogen activator Drugs 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003998 snake venom Substances 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000002849 elastaseinhibitory effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003106 tissue adhesive Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 229940049370 fibrinolysis inhibitor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0089599A AT500670A1 (de) | 1999-05-19 | 1999-05-19 | Arzneimittel zur lokalen anwendung |
| PCT/AT2000/000141 WO2000071153A2 (de) | 1999-05-19 | 2000-05-19 | Arzneimittel zur lokalen anwendung, das fibrinogen, thrombin, transglutaminasen und proteinaseinhibitoren enthält |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20015510D0 NO20015510D0 (no) | 2001-11-12 |
| NO20015510L NO20015510L (no) | 2001-11-12 |
| NO329232B1 true NO329232B1 (no) | 2010-09-20 |
Family
ID=3502302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20015510A NO329232B1 (no) | 1999-05-19 | 2001-11-12 | Medikament for lokal paforing og framgangsmate for framstilling av en fibrinogenholdig losning |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20020114796A1 (hu) |
| EP (3) | EP1275397B1 (hu) |
| JP (1) | JP2003500364A (hu) |
| AT (1) | AT500670A1 (hu) |
| AU (1) | AU5198600A (hu) |
| CA (1) | CA2372929C (hu) |
| DE (1) | DE50005999D1 (hu) |
| DK (2) | DK1183043T3 (hu) |
| ES (2) | ES2499090T3 (hu) |
| HU (1) | HU226016B1 (hu) |
| MX (1) | MXPA01011859A (hu) |
| NO (1) | NO329232B1 (hu) |
| SK (1) | SK16332001A3 (hu) |
| WO (1) | WO2000071153A2 (hu) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020131933A1 (en) * | 1996-01-16 | 2002-09-19 | Yves Delmotte | Biopolymer membrane and methods for its preparation |
| AT407484B (de) | 1997-11-12 | 2001-03-26 | Bio Prod & Bio Eng Ag | Arzneimittel zur förderung der wundheilung |
| WO2002030446A2 (en) * | 2000-10-13 | 2002-04-18 | Baxter International Inc. | Reduction or prevention of post-surgical adhesion formation with fibrinogen |
| WO2002030445A2 (en) * | 2000-10-13 | 2002-04-18 | Baxter International Inc. | Fibrinogen plus a non-plasmin-acting fibrinolysis inhibitor for the reduction or prevention of adhesion formation |
| PT1351697E (pt) * | 2001-01-18 | 2013-12-24 | Bio Prod & Bio Eng Ag | Medicamentos para estimulação da regeneração de tecidos |
| US8529956B2 (en) | 2002-03-18 | 2013-09-10 | Carnell Therapeutics Corporation | Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom |
| US8293530B2 (en) | 2006-10-17 | 2012-10-23 | Carnegie Mellon University | Method and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom |
| US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1380290A1 (en) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-beta structure pathway and its therapeutic relevance |
| GB0216002D0 (en) * | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
| US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
| EP1910844B1 (en) | 2005-07-13 | 2012-04-18 | Crossbeta Biosciences B.V. | Cross-beta structure binding compounds |
| US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
| CA2615078A1 (en) * | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | Methods for determining the effect of a treatment on the cross-.beta. structure content of a protein; selection of treatments and uses thereof |
| US8529958B2 (en) | 2006-10-17 | 2013-09-10 | Carmell Therapeutics Corporation | Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom |
| EP2058000A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Immunogenic compositions capable of activating T cells |
| EP2293776B8 (de) | 2008-06-23 | 2016-05-11 | Bio-Products & Bio-Engineering Aktiengesellschaft | Lagerstabiles, funktionell intaktes virus-inaktiviertes fibrinogen |
| DK2471902T3 (en) * | 2009-08-25 | 2018-08-06 | Servicio Andaluz De Salud | Preparation of artificial tissues by tissue engineering with agarose-fibrin biomaterials |
| JP6875619B2 (ja) * | 2015-02-26 | 2021-05-26 | 株式会社細胞応用技術研究所 | 多血小板血漿の保存方法 |
| IL247821A0 (en) * | 2016-09-14 | 2017-01-31 | Omrix Biopharmaceuticals Ltd | Adhesive preparations and their use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT359653B (de) * | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
| ATE20824T1 (de) * | 1981-06-25 | 1986-08-15 | Serapharm Gmbh & Co Kg | Angereichertes plasmaderivat zur unterstuetzung von wundverschluss und wundheilung. |
| US4442655A (en) * | 1981-06-25 | 1984-04-17 | Serapharm Michael Stroetmann | Fibrinogen-containing dry preparation, manufacture and use thereof |
| DE3622642A1 (de) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| SE9101853D0 (sv) * | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | Improved tissue ashesive |
| EP0534178B1 (en) * | 1991-09-27 | 2001-04-18 | Omrix Biopharmaceuticals S.A. | Improved tissue glue prepared by using cryoprecipitate |
| WO1993013207A2 (en) * | 1991-12-31 | 1993-07-08 | Zymogenetics, Inc. | Novel human transglutaminases |
| US5254536A (en) * | 1992-01-10 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Therapeutic utility of plasminogen activator inhibitor-1 to control bleeding |
| EP0598133B1 (en) * | 1992-04-21 | 2000-03-29 | Ajinomoto Co., Inc. | Remedy for wound |
| JPH0654897A (ja) * | 1992-08-08 | 1994-03-01 | Chemo Sero Therapeut Res Inst | フィブリノーゲン含有製剤 |
| CN1091315A (zh) * | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | 血纤维蛋白封闭剂组合物及其使用方法 |
| JP3620055B2 (ja) * | 1994-01-31 | 2005-02-16 | 味の素株式会社 | 創傷治療剤 |
| AT406120B (de) * | 1997-08-28 | 2000-02-25 | Immuno Ag | Gewebekleber |
| AT407117B (de) * | 1997-09-19 | 2000-12-27 | Immuno Ag | Fibrinschwamm |
-
1999
- 1999-05-19 AT AT0089599A patent/AT500670A1/de not_active Application Discontinuation
-
2000
- 2000-05-19 EP EP02015881.2A patent/EP1275397B1/de not_active Expired - Lifetime
- 2000-05-19 EP EP00936524A patent/EP1183043B1/de not_active Expired - Lifetime
- 2000-05-19 DK DK00936524T patent/DK1183043T3/da active
- 2000-05-19 JP JP2000619455A patent/JP2003500364A/ja active Pending
- 2000-05-19 DE DE50005999T patent/DE50005999D1/de not_active Expired - Lifetime
- 2000-05-19 MX MXPA01011859A patent/MXPA01011859A/es active IP Right Grant
- 2000-05-19 WO PCT/AT2000/000141 patent/WO2000071153A2/de active IP Right Grant
- 2000-05-19 HU HU0200856A patent/HU226016B1/hu not_active IP Right Cessation
- 2000-05-19 DK DK02015881.2T patent/DK1275397T3/da active
- 2000-05-19 CA CA2372929A patent/CA2372929C/en not_active Expired - Fee Related
- 2000-05-19 SK SK1633-2001A patent/SK16332001A3/sk unknown
- 2000-05-19 AU AU51986/00A patent/AU5198600A/en not_active Abandoned
- 2000-05-19 ES ES02015881.2T patent/ES2499090T3/es not_active Expired - Lifetime
- 2000-05-19 ES ES00936524T patent/ES2218167T3/es not_active Expired - Lifetime
- 2000-05-19 EP EP05018135A patent/EP1632246A3/de not_active Withdrawn
-
2001
- 2001-11-12 NO NO20015510A patent/NO329232B1/no not_active IP Right Cessation
- 2001-11-16 US US09/998,575 patent/US20020114796A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0200856A2 (hu) | 2002-07-29 |
| CA2372929C (en) | 2011-11-15 |
| ES2218167T3 (es) | 2004-11-16 |
| WO2000071153A3 (de) | 2001-04-26 |
| CA2372929A1 (en) | 2000-11-30 |
| DK1275397T3 (da) | 2014-09-22 |
| AT500670A1 (de) | 2006-02-15 |
| DK1183043T3 (da) | 2004-08-09 |
| HUP0200856A3 (en) | 2004-11-29 |
| EP1183043B1 (de) | 2004-04-07 |
| AU5198600A (en) | 2000-12-12 |
| NO20015510D0 (no) | 2001-11-12 |
| EP1275397A3 (de) | 2003-07-02 |
| EP1275397B1 (de) | 2014-08-06 |
| NO20015510L (no) | 2001-11-12 |
| WO2000071153A2 (de) | 2000-11-30 |
| EP1632246A3 (de) | 2009-03-11 |
| DE50005999D1 (de) | 2004-05-13 |
| EP1275397A2 (de) | 2003-01-15 |
| JP2003500364A (ja) | 2003-01-07 |
| ES2499090T3 (es) | 2014-09-26 |
| EP1183043A2 (de) | 2002-03-06 |
| HU226016B1 (en) | 2008-02-28 |
| EP1632246A2 (de) | 2006-03-08 |
| US20020114796A1 (en) | 2002-08-22 |
| SK16332001A3 (sk) | 2002-05-09 |
| MXPA01011859A (es) | 2003-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329232B1 (no) | Medikament for lokal paforing og framgangsmate for framstilling av en fibrinogenholdig losning | |
| US6825323B2 (en) | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same | |
| AU2003234743B2 (en) | Storage-stable, liquid fibrinogen formulation | |
| Chiti et al. | Fibrin in reproductive tissue engineering: a review on its application as a biomaterial for fertility preservation | |
| AU724715B2 (en) | A stabilized mixture comprising fibrinogen | |
| JP5801789B2 (ja) | トロンビンを含まない生物学的接着剤及びその医薬としての使用 | |
| EP0856317A1 (en) | A stabilized mixture comprising fibrinogen | |
| WO1996040033A1 (en) | Non-biological patch for hemostasis | |
| US20060148698A1 (en) | Storage-stable fibrinogen solutions | |
| JP3009741B2 (ja) | 骨組織の局所的形成のためのプラスミノーゲンアクティベーターの使用 | |
| Reiner | Fibrin glue increasingly popular for topical surgical hemostasis | |
| JP2005505581A (ja) | 貯蔵安定なヒトフィブリノーゲン溶液 | |
| EP1351705B1 (en) | Compositions for treatement of hemorrhaging with activated factor viia in combination with fibrinogen | |
| AU2001227771A1 (en) | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen | |
| US20030224994A1 (en) | Storage stable liquid sealer protein complex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BIO & BIO LICENSING SA, LU |
|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BIO PRODUCTS & BIO-ENGINEERING AKTIENGESELLS, AT |
|
| MM1K | Lapsed by not paying the annual fees |